基于硫化的化合物:具有抗氧化特性的癌细胞抑制剂
Olga Garbuz1, Emil Ceban2, Dorin Istrati2
1Laboratory of Systematics and Molecular Phylogenetics, Institute of Zoology, Moldova State University, 1 Academiei Street, MD-2028 Chisinau, Moldova.
Molecules (Basel, Switzerland)
|May 14, 2025
概括
西米卡巴化合物表现出强烈的抗癌作用,毒性低于化疗. 对它们的结构-活性关系和协调化学的进一步研究可能会导致改善癌症治疗.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 西米卡巴衍生物正在研究它们的抗增殖和抗氧化特性.
- 氧化应激是癌症进展的关键因素,使抗氧化化合物有价值.
- 现有的化疗剂往往具有显著的副作用.
研究的目的:
- 审查基于硫西米巴的化合物作为潜在的癌症疗法.
- 要突出具有优越的抗增殖活性和降低毒性的化合物.
- 分析结构-活性关系,以优化药物设计.
主要方法:
- 关于二氧化和二氧化化合物的文献综述.
- 结构-活动关系 (SARs) 的分析.
- 探索3D金属离子的协调化学.
主要成果:
- 特定的类西西马巴化合物显示出强大的抗增殖作用.
- 与传统化疗相比,这些化合物具有较低的毒性.
- 结构特征显著影响化合物的疗效.
结论:
- 西米卡巴为传统的癌症治疗提供了有希望的替代方案.
- 对生物机制和结构优化的进一步研究是有必要的.
- 协调化学和结构修饰可能产生新的,选择性的抗癌剂.
更多相关视频
相关概念视频
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Prevention
6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.0K
Positive Regulator Molecules
105.6K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.6K


